Evidence map›Paper›PMID 14990704›Full record

ArticleJournal of virology2004

Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.

Shannon L Taylor, Paul R Kinchington, Andrew Brooks, Jennifer F Moffat

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Shannon L TaylorDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, USA.
Paul R Kinchington
Andrew Brooks
Jennifer F Moffat
SUNY Upstate Medical University · USUniversity of Pittsburgh · USUniversity of Rochester · US

Funding

Cdk inhibitors: novel antivirals for VZVR01AI052168 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI MOFFAT, JENNIFER F. · 2003 to 2007
$1.3M
CONTROL OF RETINAL GENES BY THE OPTIC NERVE ENVIRONMENTR01EY007397 · NEI · STANFORD UNIVERSITY · PI SKENE, J H PATE · 1987 to 1999
–
NEI NIH HHS R01 EY07397NIAID NIH HHS R01 AI052168
6 · The paper itself

Abstract

Understanding the interactions between varicella-zoster virus (VZV) and host cells can be addressed by using small molecule inhibitors of cellular enzymes. Roscovitine (Rosco) is a purine derivative that inhibits cyclin-dependent kinase 1 (cdk1), cdk2, cdk5, cdk7, and cdk9, which are key regulators of the cell cycle and transcription. Herpesviruses are known to interact with cell cycle proteins; thus, the antiviral effects of Rosco on VZV growth were evaluated. In a plaque reduction assay, 25 micro M Rosco prevented VZV replication, and the antiviral effect was reversible for at least up to 24 h posttreatment. Rosco also reduced expression of the major transactivator, IE62, over 48 h. Confocal microscopy studies indicated that Rosco caused the immediate-early proteins ORF4 and IE62 to abnormally localize in infected cells and prevented cell-cell spread of VZV over 48 h. Rosco was found to inhibit VZV DNA synthesis as measured by real-time PCR, and this technique was used to estimate the 50% effective concentration (EC(50)) of 14 micro M. This value was close to the EC(50) estimate of 12 micro M determined from plaque reduction assays. At 25 micro M, Rosco was not cytotoxic over 48 h in a neutral red uptake assay, and proliferation was slowed as the cells accumulated in a G(2)-like state. These results demonstrate the importance of cdk's in VZV replication and suggest that cdk inhibitors could serve as useful VZV antivirals.

Indexed as

Antiviral AgentsApoptosisCell CycleCell Line, TumorCyclin-Dependent KinasesHerpesvirus 3, HumanHumansImmediate-Early ProteinsPurinesRoscovitineViral Plaque AssayVirus ReplicationAntiviral AgentsCyclin-Dependent KinasesImmediate-Early ProteinsPurinesRoscovitine

Identifiers

PMID14990704
PMCPMC353735
OpenAlexW2117293233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.